Dermatan sulphate in urine reflects the extent of skin affection in psoriasis.
The investigation included 15 psoriatic patients and 14 healthy controls. By using a simple method based on susceptibility to chondroitinases the excretion of dermatan sulphate, chondroitin-4/6-sulphate and heparan sulphate in the psoriatics was found to be increased with 104, 62 and 47% from uronic acid mean excretions of 1.97, 6.37 and 5.10 mumol/24 h, respectively. The excretion of hydroxyproline was not increased. In both groups the excretion of hyaluronic acid was insignificant. The absolute increase in the excretion of a major skin component like dermatan sulphate was exceeded by the excretion of chondroitin-4/6-sulphate and heparan sulphate which are both small components of skin. This indicates a comparatively high turnover of those two fractions in psoriatic lesions. The fact, that only the excretion of dermatan sulphate correlated with the fraction of skin surface involved in the psoriatic disease, indicated an important origin of this fraction, as well as the possibility of dermatan sulphate as a means of following dermal metabolism.
D000328:Adult; D000368:Aged; D002807:Chondroitin / Q000031:analogs & derivatives*; D002809:Chondroitin Sulfates / Q000652:urine; D002810:Chondroitinases and Chondroitin Lyases; D003871:Dermatan Sulfate / Q000652:urine*; D004588:Electrophoresis, Cellulose Acetate; D005260:Female; D006497:Heparan Sulfate / Q000652:urine; D006801:Humans; D006820:Hyaluronic Acid / Q000652:urine; D006909:Hydroxyproline / Q000652:urine; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000652:urine*
D002807:Chondroitin; D002809:Chondroitin Sulfates; D002810:Chondroitinases and Chondroitin Lyases; D003871:Dermatan Sulfate; D006497:Heparan Sulfate; D006820:Hyaluronic Acid; D006909:Hydroxyproline